Incidence and Risk Factors of Tenofovir Disoproxil Fumarate Induced Nephrotoxicity and Renal Function Recovery, a Hospital Case-Control Study
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The incidence of tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity ranges from 15.8 to 19.3 percent. Following cessation of TDF, approximately one-half of patients with nephrotoxicity regained full renal functions. This study aimed to determine the incidence and risk factors for nephrotoxicity, as well as the complete recovery of renal function, in human immunodeficiency virus (HIV)-infected patients receiving TDF regimens. Materials and Methods: This was a retrospective case-control study of HIV-positive patients who received TDF regimens from 2 tertiary hospitals between 2012 and 2018. Signs of TDF-induced renal dysfunction, defined as having estimated glomerular filtration rate (eGFR) decline of greater than 25%, and proximal renal tubulopathy (PRT) were followed for 48 months. After discontinuing TDF due to nephrotoxicity, the renal parameters of patients were monitored for 48 months. Univariate and multivariate regression analyses were used to determine the factors associated with TDF-induced nephrotoxicity and renal function recovery. Results: Twelve percent of 3,214 TDF-treated patients were diagnosed with renal dysfunction, whereas 303 patients (15.20%) were diagnosed with PRT. TDF-induced renal dysfunction was associated with older age (odds ratio [OR] = 2.851), smoking (OR = 1.972), and TDF use for more than 3 years (OR 1.928). Receiving trimethoprim-sulfamethoxazole (TMP/SMX) or nonsteroidal anti-inflammatory drugs (NSAIDs) and being elderly were associated with PRT (OR = 4.727, 4.313, and 3.357, respectively). Following the discontinuation of TDF, 12.96% of patients regained full renal function. Elderly patients and those taking renin-angiotensin-aldosterone system (RAAS) inhibitors or protease inhibitors (PIs) had a lower likelihood of full recovery (OR = 0.811, 0.793, 0.582, respectively). One-third experienced PRT recovery, whereas RAAS inhibitors use, old age, and receiving PIs decreased the likelihood of PRT recovery (OR = 0.709, 0.504, 0.311, respectively). TDF cessation at an eGFR greater than 60 mL/min/1.73 m2 increased the likelihood of renal function recovery and PRT by 4.07 and 2.11 times, respectively. Conclusion: Twelve percent and 15 percent of patients receiving TDF developed renal dysfunction and PRT, respectively. Age, TMP/SMX, NSAIDs, and long-term TDF exposure were independent risk factors for TDF-induced nephrotoxicity. Thirteen and thirty-three percent of patients with renal dysfunction and PRT recovered from their conditions, respectively. The discontinuation of TDF at an eGFR greater than 60 mL/min/1.73 m2 was advantageous for the recovery of renal function and PRT.
Abstract
Background: The incidence of tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity ranges from 15.8 to 19.3 percent. Following cessation of TDF, approximately one-half of patients with nephrotoxicity regained full renal functions. This study aimed to determine the incidence and risk factors for nephrotoxicity, as well as the complete recovery of renal function, in human immunodeficiency virus (HIV)-infected patients receiving TDF regimens. Materials and Methods: This was a retrospective case-control study of HIV-positive patients who received TDF regimens from 2 tertiary hospitals between 2012 and 2018. Signs of TDF-induced renal dysfunction, defined as having estimated glomerular filtration rate (eGFR) decline of greater than 25%, and proximal renal tubulopathy (PRT) were followed for 48 months. After discontinuing TDF due to nephrotoxicity, the renal parameters of patients were monitored for 48 months. Univariate and multivariate regression analyses were used to determine the factors associated with TDF-induced nephrotoxicity and renal function recovery. Results: Twelve percent of 3,214 TDF-treated patients were diagnosed with renal dysfunction, whereas 303 patients (15.20%) were diagnosed with PRT. TDF-induced renal dysfunction was associated with older age (odds ratio [OR] = 2.851), smoking (OR = 1.972), and TDF use for more than 3 years (OR 1.928). Receiving trimethoprim-sulfamethoxazole (TMP/SMX) or nonsteroidal anti-inflammatory drugs (NSAIDs) and being elderly were associated with PRT (OR = 4.727, 4.313, and 3.357, respectively). Following the discontinuation of TDF, 12.96% of patients regained full renal function. Elderly patients and those taking renin-angiotensin-aldosterone system (RAAS) inhibitors or protease inhibitors (PIs) had a lower likelihood of full recovery (OR = 0.811, 0.793, 0.582, respectively). One-third experienced PRT recovery, whereas RAAS inhibitors use, old age, and receiving PIs decreased the likelihood of PRT recovery (OR = 0.709, 0.504, 0.311, respectively). TDF cessation at an eGFR greater than 60 mL/min/1.73 m2 increased the likelihood of renal function recovery and PRT by 4.07 and 2.11 times, respectively. Conclusion: Twelve percent and 15 percent of patients receiving TDF developed renal dysfunction and PRT, respectively. Age, TMP/SMX, NSAIDs, and long-term TDF exposure were independent risk factors for TDF-induced nephrotoxicity. Thirteen and thirty-three percent of patients with renal dysfunction and PRT recovered from their conditions, respectively. The discontinuation of TDF at an eGFR greater than 60 mL/min/1.73 m2 was advantageous for the recovery of renal function and PRT.
참고문헌 (40)
- "Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 16 July 2021"[URL]
- "Guidelines for the use of antiretroviral agents in adults and adolescents with HIV"[URL]
- "European AIDS Clinical Society (EACS)"[URL]
- The Korean Society for AIDS, "Summary of 2021 Clinical Guidelines for the Diagnosis and Treatment of HIV", AIDS in HIV-infected Koreans, 2021, pp.53(3), 592~616[DOI]
- "Thailand national guidelines on HIV/AIDS treatment and prevention 2021/2022"[URL]
- Tanuma J, "Renal dysfunction during tenofovir use in a regional cohort of HIV-infected individuals in the Asia-Pacific", PLoS One, 11, pp.e0161562~ (2016)
- Madeddu G, "Tenofovir renal safety in HIV-infected patients : results from the SCOLTA Project", Biomed Pharmacother, 62, pp.6~11 (2008)
- Manosuthi W, "Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting", Southeast Asian J Trop Med Public Health, 42, pp.643~650 (2011)
- Chaisiri K, "Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight", Curr HIV Res, 8, pp.504~509 (2010)
- 이정은, "Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea", The Korean Journal of Internal Medicine, 34(2), pp.409~417 (2019), 대한내과학회[DOI]
- Ojeh BV, "Incidence and predictors of tenofovir disoproxil fumarate-induced renal impairment in HIV infected Nigerian patients", Germs, 8, pp.67~76 (2018)
- Quesada PR, "Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients", Int J Clin Pharm, 37, pp.865~872 (2015)
- Kiertiburanakul S, "Monitoring of renal function among HIV-infected patients receiving tenofovir in a resource-limited setting", J Int Assoc Physicians AIDS Care(Chic), 10, pp.297~302 (2011)
- Nelson MR, "The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults : the first 4 years", AIDS, 21, pp.1273~1281 (2007)
- Debeb SG, "Tenofovir disoproxil fumarate-associated renal dysfunction among adult people living with HIV at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, 2019 : a comparative retrospective cohort study", HIV AIDS(Auckl), 13, pp.491~503 (2021)
- Fernandez-Fernandez B, "Tenofovir nephrotoxicity : 2011 update", Aids Res Treat, 2011, pp.354908~ (2011)
- Hall AM, "Tenofovir-associated kidney toxicity in HIV-infected patients : a review of the evidence", Am J Kidney Dis, 57, pp.773~780 (2011)
- Bonjoch A, "High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy", Antiviral Res, 96, pp.65~69 (2012)
- Seo Jun-Won, "Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients", Infection and Chemotherapy, 52(3), pp.381~388 (2020), 대한감염학회[DOI]
- Goicoechea M, "Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy", J Infect Dis, 197, pp.102~108 (2008)
- Jose S, "Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure", J Infect Dis, 210, pp.363~373 (2014)
- Nishijima T, "Renal function declines more in tenofovir-than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection", PLoS One, 7, pp.e29977~ (2012)
- Aswatiwong S, "Tenofovir and risk of deficient renal function in HIV", AIDS patients at Krabi hospital, 2021, pp.1, 35~44
- Chumchit C, "Factors affecting renal adverse reactions in HIV infected patients receiving tenofovir disoproxil fumarate at Damnoen Saduak Hospital. Thai Pharmaceut", Health Sci J, 16, pp.219~227 (2021)
- Suwan D, "Incidence and Factors associated with Tenofovir-induced nephrotoxicity in HIV infected patients in Nakornping Hospital", J Nakornping Hosp, 11 (2020)
- Chayangsu S, "Decreased renal function in HIV-infected patients receiving tenofovir disoproxil fumarate-based antiretroviral regimen", Medical Journal of Sisaket Surin Buriram Hospitals, 32, pp.1~11 (2018)
- Cha A, "Reversibility of renal dysfunction after discontinuation of tenofovir", J Am Pharm Assoc, 56, pp.280~283 (2016)
- Pichpattana M, "Incidence of tenofovir disoproxil fumarate induced proximal tubulopathy in HIV-infected patients", J Infect Dis Antimicrob Agents, 33, pp.33~55 (2016)
- Lucas GM, "Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV : 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America", Clin Infect Dis, 59, pp.e96~138 (2014)
- Hoang CQ, "Determinants of risk factors for renal impairment among HIV-infected patients treated with tenofovir disoproxil fumarate-based antiretroviral regimen in Southern Vietnam", BioMed Res Int, 2020, pp.7650104~ (2020)
- Daudon M, "Drug-Induced Kidney Stones and Crystalline Nephropathy : Pathophysiology, Prevention and Treatment", Drugs, 78, pp.163~201 (2018)
- Fraser TN, "Acute kidney injury associated with trimethoprim", sulfamethoxazole, 2012, pp.67, 1271~1277
- Zhang X, "Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease : systematic review and meta-analysis", BMC Nephrol, 18, pp.256~ (2017)
- Dixit M, "Significant acute kidney injury due to non-steroidal anti-inflammatory drugs : inpatient setting", Pharmaceuticals(Basel), 3, pp.1279~1285 (2010)
- Nishijima T, "Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients : a retrospective cohort study of Japanese patients", PLoS One, 6, pp.e22661~ (2011)
- Yacoub R, "Association between smoking and chronic kidney disease : a case control study", BMC Public Health, 10, pp.731~ (2010)
- Scherzer R, "Association of tenofovir exposure with kidney disease risk in HIV infection", AIDS, 26, pp.867~875 (2012)
- Avihingsanon A, "HIV-NAT 114 study team. Plasma tenofovir concentrations and proximal tubular dysfunction in HIV-infected adults receiving tenofovir in Thailand", J AIDS Clin Res, 6, pp.1000477~ (2015)
- Tong L, "Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro", Antimicrob Agents Chemother, 51, pp.3498~3504 (2007)
- Azar M, "The elderly patient with low eGFR : beyond the numbers", R I Med J(2013), 97, pp.19~23 (2014)